$12.25
Live
0.41%
Downside
Day's Volatility :3.94%
Upside
3.54%
14.29%
Downside
52 Weeks Volatility :64.65%
Upside
58.75%
Period | Quanterix Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -14.17% | 3.6% | 0.0% |
6 Months | -21.6% | 10.2% | 0.0% |
1 Year | -35.71% | 19.6% | 0.0% |
3 Years | -74.63% | 16.8% | -23.0% |
Market Capitalization | 490.5M |
Book Value | $8.77 |
Earnings Per Share (EPS) | -1.04 |
Wall Street Target Price | 19.93 |
Profit Margin | -30.71% |
Operating Margin TTM | -38.13% |
Return On Assets TTM | -7.82% |
Return On Equity TTM | -11.48% |
Revenue TTM | 129.3M |
Revenue Per Share TTM | 3.4 |
Quarterly Revenue Growth YOY | 10.8% |
Gross Profit TTM | 46.8M |
EBITDA | -45.9M |
Diluted Eps TTM | -1.04 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.97 |
EPS Estimate Next Year | -0.88 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.23 |
What analysts predicted
Upside of 62.69%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 37.6M | ↑ 64.52% |
Net Income | -31.0M | ↑ 14.9% |
Net Profit Margin | -82.5% | ↑ 35.62% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 56.7M | ↑ 50.76% |
Net Income | -40.8M | ↑ 31.41% |
Net Profit Margin | -71.91% | ↑ 10.59% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 86.4M | ↑ 52.25% |
Net Income | -31.5M | ↓ 22.71% |
Net Profit Margin | -36.5% | ↑ 35.41% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 110.6M | ↑ 27.99% |
Net Income | -57.7M | ↑ 82.96% |
Net Profit Margin | -52.18% | ↓ 15.68% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 105.0M | ↓ 5.07% |
Net Income | -96.7M | ↑ 67.63% |
Net Profit Margin | -92.14% | ↓ 39.96% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 121.1M | ↑ 15.42% |
Net Income | -32.3M | ↓ 66.56% |
Net Profit Margin | -26.69% | ↑ 65.45% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 28.2M | ↑ 10.24% |
Net Income | -6.1M | ↓ 67.19% |
Net Profit Margin | -21.62% | ↑ 51.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 30.9M | ↑ 9.35% |
Net Income | -6.1M | ↓ 0.64% |
Net Profit Margin | -19.64% | ↑ 1.98% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 30.8M | ↓ 0.12% |
Net Income | -7.8M | ↑ 27.94% |
Net Profit Margin | -25.16% | ↓ 5.52% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.5M | ↑ 2.32% |
Net Income | -12.4M | ↑ 59.95% |
Net Profit Margin | -39.33% | ↓ 14.17% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 32.1M | ↑ 1.64% |
Net Income | -10.1M | ↓ 18.83% |
Net Profit Margin | -31.41% | ↑ 7.92% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 34.4M | ↑ 7.22% |
Net Income | -9.5M | ↓ 5.95% |
Net Profit Margin | -27.55% | ↑ 3.86% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 67.6M | ↓ 26.31% |
Total Liabilities | 26.1M | ↑ 0.61% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 170.0M | ↑ 151.3% |
Total Liabilities | 41.3M | ↑ 58.38% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 271.0M | ↑ 59.48% |
Total Liabilities | 64.9M | ↑ 57.22% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 501.5M | ↑ 85.03% |
Total Liabilities | 60.6M | ↓ 6.69% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 434.2M | ↓ 13.42% |
Total Liabilities | 75.3M | ↑ 24.24% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 425.0M | ↓ 2.12% |
Total Liabilities | 78.1M | ↑ 3.75% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 427.3M | ↓ 1.59% |
Total Liabilities | 70.0M | ↓ 7.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 429.2M | ↑ 0.44% |
Total Liabilities | 73.9M | ↑ 5.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 429.0M | ↓ 0.04% |
Total Liabilities | 75.7M | ↑ 2.49% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 425.0M | ↓ 0.94% |
Total Liabilities | 78.1M | ↑ 3.16% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 411.7M | ↓ 3.12% |
Total Liabilities | 70.3M | ↓ 9.95% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 411.3M | ↓ 0.11% |
Total Liabilities | 74.5M | ↑ 6.01% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.7M | ↑ 29.92% |
Investing Cash Flow | -5.5M | ↑ 381.8% |
Financing Cash Flow | -78.0K | ↓ 100.11% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.2M | ↓ 8.82% |
Investing Cash Flow | -25.4M | ↑ 365.27% |
Financing Cash Flow | 116.2M | ↓ 149070.51% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.4M | ↓ 10.78% |
Investing Cash Flow | -626.0K | ↓ 97.53% |
Financing Cash Flow | 96.2M | ↓ 17.18% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.9M | ↑ 105.04% |
Investing Cash Flow | -6.3M | ↑ 912.46% |
Financing Cash Flow | 270.8M | ↑ 181.39% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -48.3M | ↑ 0.76% |
Investing Cash Flow | -11.2M | ↑ 76.81% |
Financing Cash Flow | 2.3M | ↓ 99.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.5M | ↑ 132.32% |
Investing Cash Flow | -136.0K | ↓ 91.47% |
Financing Cash Flow | 551.0K | ↓ 22.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 633.0K | ↓ 106.66% |
Investing Cash Flow | -648.0K | ↑ 376.47% |
Financing Cash Flow | 139.0K | ↓ 74.77% |
Sell
Neutral
Buy
Quanterix Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Quanterix Corporation | -7.99% | -21.6% | -35.71% | -74.63% | -35.71% |
Stryker Corporation | 0.83% | 12.78% | 40.21% | 33.69% | 71.83% |
Boston Scientific Corp. | 4.85% | 29.48% | 75.68% | 96.28% | 127.87% |
Edwards Lifesciences Corp. | 4.32% | -19.19% | 1.77% | -39.29% | -7.22% |
Abbott Laboratories | 3.99% | 11.51% | 24.65% | -4.53% | 46.22% |
Medtronic Plc | 2.65% | 14.48% | 27.42% | -24.18% | -13.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Quanterix Corporation | NA | NA | NA | -0.97 | -0.11 | -0.08 | NA | 8.77 |
Stryker Corporation | 40.15 | 40.15 | 2.64 | 12.01 | 0.19 | 0.07 | 0.01 | 51.86 |
Boston Scientific Corp. | 70.26 | 70.26 | 2.14 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 27.67 | 27.67 | 3.65 | 2.6 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 35.83 | 35.83 | 4.31 | 4.67 | 0.14 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 30.23 | 30.23 | 1.67 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Quanterix Corporation | Buy | $490.5M | -35.71% | NA | -30.71% |
Stryker Corporation | Buy | $137.1B | 71.83% | 40.15 | 16.12% |
Boston Scientific Corp. | Buy | $127.3B | 127.87% | 70.26 | 12.0% |
Edwards Lifesciences Corp. | Buy | $42.3B | -7.22% | 27.67 | 23.74% |
Abbott Laboratories | Buy | $205.1B | 46.22% | 35.83 | 13.65% |
Medtronic Plc | Buy | $115.2B | -13.49% | 30.23 | 12.06% |
Insights on Quanterix Corporation
Revenue is up for the last 4 quarters, 30.83M → 34.38M (in $), with an average increase of 3.5% per quarter
Netprofit is up for the last 3 quarters, -12.40M → -9.47M (in $), with an average increase of 14.8% per quarter
In the last 1 year, Boston Scientific Corp. has given 76.0% return, outperforming this stock by 110.6%
In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 170.9%
AllianceBernstein L.P.
BlackRock Inc
Vanguard Group Inc
Portolan Capital Management, LLC
Ameriprise Financial Inc
Granahan Investment Management Inc..
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
Organization | Quanterix Corporation |
Employees | 441 |
CEO | Dr. Masoud Toloue Ph.D. |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$12.25
-4.15%
Invesco Bulletshares 2025 Hi
$12.25
-4.15%
Schwab International Dividend Equity Etf
$12.25
-4.15%
Blockchain Coinvestors Acquisition Corp.
$12.25
-4.15%
Allgiant Travel Company
$12.25
-4.15%
Rogers Corp
$12.25
-4.15%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$12.25
-4.15%
Iheartmedia
$12.25
-4.15%
Lightpath Technologies Inc
$12.25
-4.15%